Not forgetting insurance companies at all. If Lovaza was able to get such a HUGE percentage of their usage off label, then so should Vascepa. But that's not happening because its not getting prescribed, pure & simple. Higher priced generics just took 1/2 their business for crying out loud. From day one we expected our superior product to just step right into Lovaza business & waltz away with it in both direct & off-label use. And now we're supposed to expect that ANCHOR will succeed? There was a time I thought so, but that was a different time indeed. PS I am using off-label w/ BC/BS with no problem. Excuses are getting thin.
Why do you respond to these guys? And why are these guys hanging around this message board if they think the game is over.
Too low to go higher...I thought I'd heard everything up till now..This stock was laid low by the FDA action and doubts over REDUCE-IT. If these problems get cleared up and Amarin gets the 35 mil man cohort the stock will go to $20 plus faster than boiled asparagus.
Market Data 
Markets 
AI
